FansUnite Signs Multiple Data Provider Partnerships for Chameleon B2B Platform

Partnerships with Pariplay, SportsIQ, Pythia Sports and other leading data providers will strengthen FansUnite's technology platform

FansUnite Entertainment Inc. (CSE: FANS) (OTCQX: FUNFF) ("FansUnite" or the "Company") is pleased to announce that its group of companies, including Askott Entertainment (Malta) Limited and E.G.G. Limited, has negotiated and signed multiple strategic vendor agreements that will further enhance its capabilities as a full-service Business-to-Consumer ("B2C") operator and Business-to-Business ("B2B") technology provider in the European, U.K and North American online gambling markets.

Most notably, the Company has signed agreements with:

Pariplay
The deal will see Pariplay's wide portfolio of proprietary and third-party content become available on FansUnite's B2B solution Chameleon, offered to iGaming, esports and sports betting operators across the globe. Pariplay is a globally recognized casino aggregator and the content will be distributed via Pariplay's Fusion™ platform which includes over 12,000 games from over 100 third-party suppliers, as well as the provider's own library of 120+ innovative and entertaining slots.

Sports IQ
The agreement will see FansUnite integrate Sports IQ's full suite of player props, including both pre-game and in-play betting across all US sports for both Business-to-Consumer and Business-to-Business. Sports IQ's products leverage tremendous automation and minimal suspensions to provide the highest quality product.

Pythia Sports
Pythia Sports is a leader in predictive modelling and trading of global Horse Racing markets and will be providing a managed pricing service for UK, Irish and International horseracing to FansUnite. Pythia draws on decades of experience in horse racing betting, using the latest AI technologies. Further, Pythia will provide a full range of derivative horseracing markets to give FansUnite clients and end-users a wide range of offerings.

Algosport
Algosport's proprietary algorithms allow FansUnite to offer same game multiples across a variety of sports, both pre-game and in-play, with cashout supported as standard. The agreement will see Algosport deliver bet builders on soccer, US sports and UK sports. In addition, Algosport recently became one of the first providers to offer Bet Builder products for eSports titles such as FIFA 2021 which has become increasingly popular.

"As we continue to expand the offerings of our technology platform, we're excited to sign deals with these industry leaders to provide the best data and most robust offerings for our customers and end-users around the world," said Scott Burton, CEO of FansUnite. "We already have a list of great partners, but with an eye to the North American markets, we are excited to add official data, props and in-play products for the major North American sports leagues to our platform and customers."

About FansUnite Entertainment Inc.

FansUnite is a global sports and entertainment company, focusing on technology related to regulated and lawful online gaming and other related products. FansUnite has produced a one-of-a-kind complete iGaming platform, with a sports and esports focus geared for the next generation of online bettors and casino players. The platform includes products for pre-match betting, in-play betting, daily fantasy, content and a certified RNG to produce casino style chance games. The platform operates multiple B2C brands and B2B software for the online gambling industry. FansUnite also looks to acquire technology platforms and assets with high growth potential in new or developing markets. The Company also provides technological solutions and services in the global gaming and entertainment industries. Its technology includes fixed/parimutuel odds, in-stream betting, live betting, casino-style games, cryptocurrency wallet and news content.

For further information, please contact:

Prit Singh, Investor Relations at FansUnite
ir@fansunite.com
(905) 510-7636

Scott Burton, Chief Executive Officer of FansUnite
scott@fansunite.com

Darius Eghdami, President of FansUnite
darius@fansunite.com

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDERS HAVE REVIEWED ‎OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

FORWARD-LOOKING STATEMENTS: Certain information contained herein may constitute "forward-‎‎‎looking information" and "forward-looking statements" with the meaning of applicable Canadian and U.S. securities legislation (collectively, "forward-looking statements"). Generally, forward-looking statements can be ‎‎‎identified by the use of forward-looking terminology such as "believes," "belief," "expects," "intends," ‎‎"anticipates," "potential," "should," "may," "will," "plans," "continue" or similar expressions to be uncertain ‎‎‎and forward-looking. Forward-looking statements may include, without limitation, statements relating to ‎‎‎future outlook and anticipated events such as: fulfillment of terms by the counterparties to vendor agreements; ability to ‎fulfill technology needs with our ‎platform and any technology from the counterparties to vendor agreements; business development ‎plans of ‎FansUnite; legal framework; the Company's unique portfolio of assets; and discussion of future plans, ‎projections, ‎objectives, estimates ‎and forecasts and the timing related thereto. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results, level of activity, performance or achievements may differ materially from those expressed or implied in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: inability to obtain or maintain license(s); risks related ‎to global pandemics, ‎including the novel ‎coronavirus (COVID-19) global health pandemic, and the spread of ‎other viruses or ‎pathogens; and influence ‎of macroeconomic developments. Additional ‎information regarding the risks and uncertainties relating to the ‎Company's business ‎are contained under ‎the heading "Risk Factors" in the Company's Short Form ‎Prospectus dated July 9, 2021 filed on its ‎issuer profile on SEDAR at www.sedar.com. Accordingly, readers should not ‎place undue ‎reliance on forward-looking ‎statements. The forward-looking ‎statements in ‎this news release are made ‎as of the date of this news release. FansUnite disclaims and does not ‎undertake to ‎update or revise any forward-looking statements, whether written or oral, that may be made from time to time, whether as a ‎result of new ‎information, future events or ‎otherwise, except as required by applicable securities laws.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/96437

News Provided by Newsfile via QuoteMedia

The Conversation (0)
Sona Nanotech's THT Cancer Studies Demonstrates Strong Efficacy in Third Preclinical Study and Plans for First-in-human Early Feasibility Study

Sona Nanotech's THT Cancer Studies Demonstrates Strong Efficacy in Third Preclinical Study and Plans for First-in-human Early Feasibility Study

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") announces results from its most recent preclinical study of its Targeted Hyperthermia Therapy ("THT") which uses the Company's patented, biocompatible gold nanorods ("GNRs") to treat certain solid cancer tumors, shrinking them and acting as an immune stimulator. Building on its success in melanoma and breast cancer studies, the Company's third preclinical efficacy study was conducted in an immunologically 'cold' colorectal cancer model ("CT26"), a model that represents the majority of human colon cancers, which do not typically respond to current standard of care immunotherapies.

In this preliminary study, whereas no mice that were given standard immunotherapy alone showed any response, 100% of mice in the THT treatment group responded to the same immunotherapy with 50% (4 out of 8) of those tumors eliminated within 12 days of treatment, as shown by the green line in Figure 1, below.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Syntheia Announces Establishment of Advisory Board and Appointment of Travel Industry Expert, Mr. John Kirk

Syntheia Announces Establishment of Advisory Board and Appointment of Travel Industry Expert, Mr. John Kirk

Syntheia Corp. ("Syntheia" or the "Company") (Syntheia.ai), CSE SYAI, Syntheia, a Canadian leader in conversational AI SaaS, is pleased to announce the establishment of its new Advisory Board. The Advisory Board will collaborate with management and the board of directors to enhance the Company's strategic direction, provide expert guidance on its commercial initiatives, offer industry insights, and shape and accelerate innovations.

As the inaugural member of the Advisory Board, Syntheia welcomes Mr. John Kirk, a leader in the travel industry. The travel sector represents a potentially significant growth market for the Company's technology.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Syntheia Enhances Inbound Customer Calls with AI-Powered Virtual Assistants, Positively Impacts Sales and Customer Satisfaction

Syntheia Enhances Inbound Customer Calls with AI-Powered Virtual Assistants, Positively Impacts Sales and Customer Satisfaction

Syntheia Corp. ("Syntheia" or the "Company") (Syntheia.ai), CSE SYAI, Syntheia, a Canadian leader in conversational AI SaaS, is transforming customer service by delivering an innovative solution that uses natural language processing (NLP) to handle inbound telephone calls with virtual assistants. Since its beta launch in June 2023, Syntheia has processed over 750,000 conversations, bringing new levels of efficiency and engagement to businesses in diverse industries.

Companies like Georgetown Hyundai, Palmieri Furniture, Campio Furniture, and Pay N Go have all embraced Syntheia's platform, highlighting its positive impact on sales and customer satisfaction.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Zero Candida Technologies Inc.  Opens the Market

Zero Candida Technologies Inc. Opens the Market

Eli Ben-Haroosh, Co-Founder and Chief Executive Officer, Zero Candida Technologies Inc. (TSXV: ZCT) ("Zero Candida" or the "Company"), joined Dani Lipkin, Managing Director, Global Innovation Sector, Toronto Stock Exchange, to open the market to celebrate the Company's new listing on the TSX Venture Exchange.

Zero Candida Technologies, Inc. (ZCT), is a medical device company bringing female healthcare into the 21st century. They are transforming the treatment of Vulvo-Vaginal Candidiasis ("VVC"), which affects 75% of women worldwide, often recurrent and increasingly drug-resistant with current treatments failing to address the root cause effectively. Free from chemicals and side effects, their AI-driven tampon-like device enables real-time data collection and transmission to physicians for personalized, at-home treatment. Beyond VVC, ZCT aims to revolutionize gynecology, improving access for underserved populations and advancing hybrid medicine.

Please refer to the Company's website here.

MEDIA CONTACT:
Victoria Gamble
Corporate Development Consultant
victoria@zero-candida.com
416-706-0332

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/231280

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
XReality Group

xReality Group Limited Chairman’s Address 2024 Annual General Meeting – 22 November 2024

xReality Group Limited (ASX:XRG) (xReality) is pleased to present xReality Group Limited’s 2024 Annual General Meeting.

Keep reading...Show less
XReality Group

Operator XR – Sales Update November 24

xReality Group Limited (ASX:XRG) (xReality) is pleased to provide the following sales update for Operator XR, a wholly owned subsidiary of xReality Group Ltd. Operator XR provides Military and Law Enforcement agencies around the world with a unique, integrated Mission Planning & Rehearsal System, which is portable, secure, and highly immersive.

Keep reading...Show less

Latest Press Releases

Related News

×